|
| 38086008 | CML and the WHO: Why? | J Clin Oncol | 2024 |
| 36881782 | MANIFEST: Pelabresib in Combination With Ruxolitinib for Janus Kinase Inhibitor Treatment-Naïve Myelofibrosis. | J Clin Oncol | 2023 |
| 37760623 | Exploring the Molecular Landscape of Myelofibrosis, with a Focus on Ras and Mitogen-Activated Protein (MAP) Kinase Signaling. | Cancers (Basel) | 2023 |
| 37439808 | A Phase Ib Trial of AVID200, a TGFβ 1/3 Trap, in Patients with Myelofibrosis. | Clin Cancer Res | 2023 |
| 36961012 | Animal Models and Their Role in Imaging-Assisted Co-Clinical Trials. | Tomography | 2023 |
| 36550198 | Pneumocystis jirovecii Infection in autologous hematopoietic stem cell transplant recipients. | Bone Marrow Transplant | 2023 |
| 34462243 | Late Responses in Patients With Chronic Myeloid Leukemia Initially Refractory to Tyrosine Kinase Inhibitors. | Clin Lymphoma Myeloma Leuk | 2022 |
| 35352806 | Epigenetic downregulation of Socs2 contributes to mutant N-Ras-mediated hematopoietic dysregulation. | Dis Model Mech | 2022 |
| 36075392 | Myeloproliferative Neoplasms, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. | J Natl Compr Canc Netw | 2022 |
| 35998053 | Multiparametric MRI to quantify disease and treatment response in mice with myeloproliferative neoplasms. | JCI Insight | 2022 |
| 32354563 | A provider's guide to primary myelofibrosis: pathophysiology, diagnosis, and management. | Blood Rev | 2021 |
| 33630025 | Assessment of Clinical Benefit of Integrative Genomic Profiling in Advanced Solid Tumors. | JAMA Oncol | 2021 |
| 33909030 | Mechanism of mutant calreticulin-mediated activation of the thrombopoietin receptor in cancers. | J Cell Biol | 2021 |
| 33613844 | Downregulation of SOX2 by inhibition of Usp9X induces apoptosis in melanoma. | Oncotarget | 2021 |
| 34607341 | Type 1 interferon to prevent leukemia relapse after allogeneic transplantation. | Blood Adv | 2021 |
| 32647323 | Fedratinib, a newly approved treatment for patients with myeloproliferative neoplasm-associated myelofibrosis. | Leukemia | 2021 |
| 31527168 | Development of 2 Bromodomain and Extraterminal Inhibitors With Distinct Pharmacokinetic and Pharmacodynamic Profiles for the Treatment of Advanced Malignancies. | Clin Cancer Res | 2020 |
| 33232476 | Determining the recommended dose of pacritinib: results from the PAC203 dose-finding trial in advanced myelofibrosis. | Blood Adv | 2020 |
| 32886902 | Myeloid/Lymphoid Neoplasms with Eosinophilia and TK Fusion Genes, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology. | J Natl Compr Canc Netw | 2020 |
| 30305729 | Leukemia inhibitory factor functions in parallel with interleukin-6 to promote ovarian cancer growth. | Oncogene | 2019 |
| 31645897 | Tumor necrosis factor related apoptosis inducing ligand (TRAIL) regulates deubiquitinase USP5 in tumor cells. | Oncotarget | 2019 |
| 30234400 | Predictive models for splenic response to JAK-inhibitor therapy in patients with myelofibrosis. | Leuk Lymphoma | 2019 |
| 31537486 | Ruxolitinib in adult patients with secondary haemophagocytic lymphohistiocytosis: an open-label, single-centre, pilot trial. | Lancet Haematol | 2019 |
| 31092894 | The first-in-human study of the pan-PIM kinase inhibitor PIM447 in patients with relapsed and/or refractory multiple myeloma. | Leukemia | 2019 |
| 31029462 | Corrigendum to "Phase 1/2 trial of glasdegib in patients with primary or secondary myelofibrosis previously treated with ruxolitinib" [Leukemia Res. 79 (2019) 38-44]. | Leuk Res | 2019 |
| 30849661 | Phase 1/2 trial of glasdegib in patients with primary or secondary myelofibrosis previously treated with ruxolitinib. | Leuk Res | 2019 |
| 29288428 | Outcomes of previously untreated elderly patients with AML: a propensity score-matched comparison of clofarabine vs. FLAG. | Ann Hematol | 2018 |
| 32914003 | Oncologists' Use of Genomic Sequencing Data to Inform Clinical Management. | JCO Precis Oncol | 2018 |
| 29908418 | The FOSSIL Study: FLAG or standard 7+3 induction therapy in secondary acute myeloid leukemia. | Leuk Res | 2018 |
| 30181422 | Chronic Myeloid Leukemia, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology. | J Natl Compr Canc Netw | 2018 |
| 29988611 | Primary myelofibrosis evolving to an aplastic appearing marrow. | Clin Case Rep | 2018 |
| 30086777 | Evaluation of an alternative ruxolitinib dosing regimen in patients with myelofibrosis: an open-label phase 2 study. | J Hematol Oncol | 2018 |
| 30545997 | Systemic Mastocytosis, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. | J Natl Compr Canc Netw | 2018 |
| 29695516 | Phase 1 study of the PI3Kδ inhibitor INCB040093 ± JAK1 inhibitor itacitinib in relapsed/refractory B-cell lymphoma. | Blood | 2018 |
| 29522138 | Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis: A Randomized Clinical Trial. | JAMA Oncol | 2018 |
| 29574002 | Treatment With JAK Inhibitors in Myelofibrosis Patients Nullifies the Prognostic Impact of Unfavorable Cytogenetics. | Clin Lymphoma Myeloma Leuk | 2018 |
| 29567798 | Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial. | Blood | 2018 |
| 29370463 | Dasatinib dose management for the treatment of chronic myeloid leukemia. | Cancer | 2018 |
| 29248719 | Usp9x Promotes Survival in Human Pancreatic Cancer and Its Inhibition Suppresses Pancreatic Ductal Adenocarcinoma In Vivo Tumor Growth. | Neoplasia | 2018 |
| 27479177 | A phase I, open-label, dose-escalation, multicenter study of the JAK2 inhibitor NS-018 in patients with myelofibrosis. | Leukemia | 2017 |
| 28198367 | Usp9x regulates Ets-1 ubiquitination and stability to control NRAS expression and tumorigenicity in melanoma. | Nat Commun | 2017 |
| 28228106 | Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial. | J Hematol Oncol | 2017 |
| 28084835 | Induction of p53 suppresses chronic myeloid leukemia. | Leuk Lymphoma | 2017 |
| 28335073 | Clinical characteristics and whole exome/transcriptome sequencing of coexisting chronic myeloid leukemia and myelofibrosis. | Am J Hematol | 2017 |
| 28982745 | NCCN Guidelines Insights: Myeloproliferative Neoplasms, Version 2.2018. | J Natl Compr Canc Netw | 2017 |
| 29163793 | Rapid, ultra low coverage copy number profiling of cell-free DNA as a precision oncology screening strategy. | Oncotarget | 2017 |
| 28783718 | Integrative clinical genomics of metastatic cancer. | Nature | 2017 |
| 28807791 | Effects of Bosutinib Treatment on Renal Function in Patients With Philadelphia Chromosome-Positive Leukemias. | Clin Lymphoma Myeloma Leuk | 2017 |
| 28842135 | New Series: SOHO 'State of the Art Updates and Next Questions'. | Clin Lymphoma Myeloma Leuk | 2017 |
| 28602585 | Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study. | Lancet Haematol | 2017 |